Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 24 Sep
Source: Bse
Fermenta Biotech Limited (FERMENTA)
Small CapPharma stocks · Small cap · NSE
Fermenta Biotech Limited operates in Enzymes & API, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 10:46 am ISTDetails
Quote21 Oct, 10:46 am IST
Base fundamentals06 Oct 2026 · screener
Latest result16 Aug, 01:36 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
72BullishSMA20 +5.3% / mo · MACD − · sector +4.2pp vs Nifty 500 (3M)
Stock trend: 54
Sector RS: 99
Sector 3M: -0.8% vs Nifty 500 -5.1%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
FERMENTAD candles · FIT view+46.6%TODAY · PROVISIONALLatest price ₹461.35 on 2026-10-21
Daily history is available from 2026-04-20; the requested 1Y window is partially covered. Today's candle is provisional from the latest intraday quote; completed-candle scans remain unchanged.
Bar
-0.2%
RSI
37
MACD hist
-9.83
52W pos
64%
2026-10-21O ₹462.30H ₹468.10L ₹451.60C ₹461.35Vol 26,952 shIntraday candle
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
FERMENTANifty PharmaNifty 500
- FERMENTA
- +3.7%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- +9.3 pp
Chart stats
19 Oct 2026- From 52W high
- -21.0%
- 52W range position
- 63%
- ATR (14)
- 6.4%
- Volume vs 20D
- 0.18x
- Avg traded value
- ₹24.8 Cr
- 20D price channel
- ₹426.3 - ₹582.7
₹582.7
₹248.9 - ₹582.7
₹29.3
Latest completed session
20-session average
63.8% annualized volatility
Research snapshot
What the evidence says now
Mixed fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · FAIR VALUE47
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad0
Revenue -10.6% · PAT -55.9% YoY
Technical
Bullish72
Price trend and sector-relative-strength timing.
Valuation
Legacy model-38.7%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence73
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 0/100Rev -11% YoY · PAT -56% YoY · margin compression
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹121.8 Cr | -10.6% | +0.2% |
| EBITDA | ₹18.1 Cr | -36.0% | -9.7% |
| Operating margin | 14.8% | -590 bps | -162 bps |
| PAT | ₹9.5 Cr | -55.9% | -48.8% |
| PAT margin | 7.8% | -803 bps | -748 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 30.00
- P/B
- 4.04
- EV/EBITDA
- 15.80
- Market Cap
- 1641.00Cr
Profitability
- ROE
- 16.40%
- ROCE
- 20.60%
- ROA
- 8.95%
- Dividend Y
- 0.67%
Growth (CAGR)
- Revenue 5Y
- 7.00%
- EPS 5Y
- 7.00%
- Revenue 3Y
- 14.00%
- EPS 3Y
- 65.00%
Balance Sheet
- Debt/Equity
- 0.28
- Interest Coverage
- 8.18×
- Altman Z
- 6.39
- Book Value
- 138.00
Cash Flow
- FCF Yield
- 3.05%
- FCF Positive Y
- 7/5
- OCF
- 93.00 Cr
- EPS TTM
- 20.28
Shareholding
- Promoter Hold
- 64.09%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 93%
Financial History
Updated 19/10/2026
Revenue
₹ CrLatest: 523+11.8% vs prev
Net Profit
₹ CrLatest: 70.0-7.9% vs prev
Return on Equity
%Latest: 17.2-17.7% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend unclear. RSI 37. Wait for confirmation.
- SMA20 rising (~5.0% over last month) — short-term momentum positive.
- RSI(14) at 37 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 21% off 52W high · 85% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
84
RS percentile
Insufficient history
1M return
-2.9%
3M return
+3.7%
6M return
+46.3%
1Y return
-
RS 1D
-2
RS 20D
-
Sector rank
#1
Industry rank
#11
Stage evidence
- At least 170 daily sessions are required for the trend-stage read.
50-DMA
price below
200-DMA
unavailable
Sector
leading
Industry
leading
Partial-history RS: the 3M and 6M weights are re-normalised because 12M history is unavailable.
Relative-strength line vs Nifty 500 (base 100)
127 observations
19 Oct 2026Value 150.04-4.26%
RS vs Nifty 500150
Valuation & peers
U-Score 47 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Valuation & peers
U-Score 47 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Financial Turnaround
Fundamental score breakdown
U band · FAIR VALUEValuation4/30
Growth8/25
Quality13/20
Balance Sheet10/15
Cash Flow8/10
Piotroski
8/9 (+5)
Penalties
-1
Raw sum
47
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
47/100 · legacy band FAIR VALUE
Positive drivers
- FCF yield is supportive at 3.0%.
- Piotroski is strong at 8/9.
- Cash flow contributes 8/10 to the score.
Main drags
- Penalty bucket subtracts 1 points.
- Fair-value margin of safety is negative at -38.7%.
- Valuation is weaker at 4/30; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
30.0
PB
4.0
EV/EBITDA
15.8
ROE
16.4%
ROCE
20.6%
FCF Yield
3.0%
Debt/Equity
0.3
MoS
-38.7%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
47
Previous: 47
Legacy U-Score band
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
-38.7%
Previous: -38.5%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
46
46
46
46
46
46
46
46
46
46
47
47
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹250.94
-83.9% MoS
Growth-justified P/E
16.4
Growth-justified Value
₹332.59
-38.7% MoS
PEG
2.68
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
WINDLAS
Small
Windlas Biotech Limited
Pharmaceuticals
match 141
49
31.6
12.2%
+36%
FAIR VALUE
AHCL
Small
Anlon Healthcare Limited
Pharmaceuticals
match 139
41
52.5
18.4%
-11%
WATCHLIST
JAGSNPHARM
Small
Jagsonpal Pharmaceuticals Limited
Pharmaceuticals
match 138
58
32.2
17.3%
+29%
FAIR VALUE
NGLFINE
Small
NGL Fine-Chem Limited
Pharmaceuticals
match 138
38
32.3
17.4%
-339%
WATCHLIST
BETA
Small
Beta Drugs Limited
Pharmaceuticals
match 136
44
48.7
18.8%
+13%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Fermenta Biotech Limited operates in Enzymes & API, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
73Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 72nd percentile of the scored universe and 63rd percentile within Pharma. Main check: results consistency is weak at 5/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
141 docs text-extracted · 15 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
72nd percentile
overall median 67 · Pharma: 63rd pctile, median 70 · Small: 75th pctile, median 66
Evidence depth
Financial-only
141 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
90
strong · capital discipline
Results
5
weak · quarterly consistency
Trust positives
- ▸Promoter holding is 64.1%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 3.4%.
- ▸7 years of positive FCF.
Trust risks
- ▸3 latest quarters had PAT decline worse than 25% YoY.
- ▸1/4 latest quarters had positive YoY revenue growth.
- ▸1/4 latest quarters had positive YoY PAT growth.
- ▸OPM spread across recent quarters is 19.2%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Fermenta Biotech Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 21 Sep
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 17 Sep
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 16 Sep - Copy of Newspaper Publication regarding notice to equity shareholders for transfer of shares to IEPF.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 26 Aug - We hereby submit newspaper publication pertaining to Notice for Special window for transfer and dematerialization of physical securities.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.